Novo Nordisk "pleased" with obesity trial results

COPENHAGEN, March 18 Mon Mar 18, 2013 7:58am EDT

Related Topics

COPENHAGEN, March 18 (Reuters) - Denmark's Novo Nordisk , the world's biggest insulin producer, said on Monday sufferers of Type 2 diabetes achieved 6 percent weight loss with one of their obesity drugs in a trial.

Novo Nordisk said subjects with Type 2 diabetes achieved 6 percent weight loss with 3 milligrams of liraglutide in the advanced Phase III trial, compared to 2 percent for people who were given a placebo.

"We are pleased about the outcome of this trial and look forward to getting the results from the two remaining trials in the SCALE programme", said Mads Krogsgaard Thomsen, chief science officer at Novo Nordisk.

The company expects to complete the two remaining Phase III trials in the programme by mid-2013. (Reporting by Johan Ahlander; Editing by Greg Mahlich)

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article